Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep

Dungu, Baptiste; Louw, Ian; Lubisi, Alison; Hunter, Paul; Teichman, Beate F. von; Bouloy, Michèle

doi:10.1016/j.vaccine.2010.04.085

Cited by 121 publications

(124 citation statements)

References 14 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…The formalin-inactivated wholevirus vaccines are safe but less immunogenic (Lubroth et al 2007). Clone 13, another live attenuated natural mutant, is now in commercial use in South Africa for the control of the disease in livestock (Muller et al 1995, Dungu et al 2010). MP12, a chemically attenuated virus derived from ZH548, an Egyptian wild-type isolate (Caplen et al 1985, Vialat et al 1997, is being evaluated as a potential vaccine for human and veterinary use.…”

mentioning

confidence: 99%

“…Strategies to develop RVFV vaccines include subunit (Schmaljohn et al 1989, Mandell et al 2010a, DNA (Spik et al 2006), viruslike particles (VLPs) , de Boer et al 2010, Kortekaas et al 2012, virus replicon particles (Kortekaas et al 2011, Dodd et al 2012, Oreshkova et al 2013), virus-vectored (Wallace et al 2006, Heise et al 2009) modified live vaccines, developed from recombinant viruses engineered using reverse genetics (Ikegami et al 2006, Bird et al 2008, Billecocq et al 2008, Habjan et al 2008, Bird et al 2011, live attenuated (Smithburn 1949, Caplen et al 1985, Muller et al 1995, Dungu et al 2010, Pittman 2012, Morrill et al 2013, and inactivated whole virus vaccines (Pittman et al 2000). Although subunit vaccines for RVFV are generally considered safe, and recently some progress has been made in their development, evaluation of immunogenicity and/or efficacy in a target species, sheep, has been performed for a few candidates (Kortekaas et al 2012, Oreshkova et al 2013).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep

Faburay

Lebedev²,

McVey³

et al. 2014

Vector-Borne and Zoonotic Diseases

View full text Add to dashboard Cite

Rift Valley fever virus (RVFV), a member of the Bunyaviridae family, is a mosquito-borne zoonotic pathogen that causes serious morbidity and mortality in livestock and humans. The recent spread of the virus beyond its traditional endemic boundaries in Africa to the Arabian Peninsula coupled with the presence of susceptible vectors in nonendemic countries has created increased interest in RVF vaccines. Subunit vaccines composed of specific virus proteins expressed in eukaryotic or prokaryotic expression systems are shown to elicit neutralizing antibodies in susceptible hosts. RVFV structural proteins, amino-terminus glycoprotein (Gn), and carboxylterminus glycoprotein (Gc), were expressed using a recombinant baculovirus expression system. The recombinant proteins were reconstituted as a GnGc subunit vaccine formulation and evaluated for immunogenicity in a target species, sheep. Six sheep were each immunized with a primary dose of 50 lg of each vaccine immunogen with the adjuvant montanide ISA25; at day 21, postvaccination, each animal received a second dose of the same vaccine. The vaccine induced a strong antibody response in all animals as determined by indirect enzyme-linked immunosorbent assay (ELISA). A plaque reduction neutralization test (PRNT 80 ) showed the primary dose of the vaccine was sufficient to elicit potentially protective virus neutralizing antibody titers ranging from 40 to 160, and the second vaccine dose boosted the titer to more than 1280. Furthermore, all animals tested positive for neutralizing antibodies at day 328 postvaccination. ELISA analysis using the recombinant nucleocapsid protein as a negative marker antigen indicated that the vaccine candidate is DIVA (differentiating infected from vaccinated animals) compatible and represents a promising vaccine platform for RVFV infection in susceptible species.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep

Faburay

Lebedev²,

McVey³

et al. 2014

Vector-Borne and Zoonotic Diseases

View full text Add to dashboard Cite

show abstract

“…This study found that cancer incidence was significantly increased with exposure. 126 All cancer diagnoses were confirmed by pathological examination, and the most commonly found cancers in both groups (75% of all cancers combined) were lymphatic, hematological, and gastrointestinal. The age adjusted incidence rate ratio was 1.64 (95 % CI 1.15-2.34), and the hazard ratio of cancer was 2.02 (95 % CI 1.41-2.88).…”

Section: Cancermentioning

confidence: 98%

“…126,127,128 In a study of 242 patients exposed to mustard gas during the Iran-Iraq war, Ebadi and colleagues found that, 34 in general, all those suffering sequelae had a lower quality of life, especially with regard to health factors. 126 These researchers also found that sequelae in three or more systems (i.e. pulmonary, ocular, and skin) were correlated with the lowest quality of life.…”

Section: Quality Of Lifementioning

confidence: 99%

Assessment of Potential Long Term Health Effects on Army Human Test Subjects of Relevant Biological and Chemical Agents, Drugs, Medications and Substances

Johnson¹

2016

View full text Add to dashboard Cite

“…40,87 Clone 13, a naturally occurring NSs deletion mutant of the Rift Valley fever virus has been demonstrated to be an effective vaccine candidate in sheep and cattle. 88,89 However, clone 13 contains a large deletion in NSs, which is possible because the nucleocapsid (N) and NSs genes are coded separately and in opposite directions on the S segment of the Rift Valley fever virus RNA. In Schmallenberg virus and other orthobunyaviruses, N and NSs overlap and are encoded by different initiation sites (start codons) in the same viral strand ( Figure 1A).…”

Section: Future Control Measuresmentioning

confidence: 99%

Schmallenberg virus: continuing a trend?

Noad¹,

Brownlie²

2013

VAAT

View full text Add to dashboard Cite

Abstract:Since its first isolation in Germany in 2011 the Schmallenberg strain of the Sathuperi virus has been detected across northern Europe. The virus is associated with neurological disease, abortion, and congenital deformities in ruminants, particularly among sheep and cattle. The rapid dissemination of the pathogen is reminiscent of the transmission of another midge-borne arbovirus, Bluetongue virus, which also spread to Europe on several separate occasions between 1998 and 2007. In this review we detail the characteristic features of the Schmallenberg virus and consider whether the virus highlights a European vulnerability for other midge-transmitted pathogens.

show abstract

Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep

Cited by 121 publications

References 14 publications

A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep

A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep

Assessment of Potential Long Term Health Effects on Army Human Test Subjects of Relevant Biological and Chemical Agents, Drugs, Medications and Substances

Schmallenberg virus: continuing a trend?

Contact Info

Product

Resources

About